曲美他嗪对缺血性心肌病患者血浆C反应蛋白及心功能的影响被引量：1

下载PDF

导出

摘要目的:分析曲美他嗪对缺血性心肌病患者血浆C反应蛋白(CRP)水平和心功能的影响。方法:缺血性心肌病患者60例,随机分为对照组(常规药物治疗)和治疗组(常规药物加曲美他嗪治疗),每组各30例,全部入选患者于观察起点及用药3个月时行6 min步行试验(6MWD)、心脏彩色超声检查及测定血浆CRP浓度,比较各组患者心功能改善情况及血浆CRP的变化。结果:两组患者治疗前后自身比较,6MWD、左室射血分数均增加,血浆CRP水平均有下降,而治疗组明显优于对照组,差异有统计学意义(P<0.05),治疗组治疗后二尖瓣舒张早期血流速度峰值/二类瓣舒张晚期血流速度峰值的比值(E/A)较前明显升高(P<0.05),而对照组无明显变化(P>0.05)。结论:在常规治疗的基础上加用曲美他嗪能改善缺血性心肌病患者的心脏收缩及舒张功能,同时能显著降低血浆CRP的水平,改善患者预后。

作者杨昆曹鸿昆付薇张云坤金志泽

机构地区云南省第二人民医院干疗科

出处《中国药师》 CAS 2011年第12期1783-1784,共2页 China Pharmacist

关键词缺血性心肌病 C反应蛋白曲美他嗪

分类号 R974.3 [医药卫生—药品]

引文网络
相关文献

参考文献9

1Fe|ker GM, ShawLK, O'connor CM. A standardized definition of is- chemic cardiomyopathy for use in clinical research [ J ]. J Am Coll Cardiol,2002,39 (2) :210-208.
2Lee l, Horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment [ J ]. European Heart Jour- nal,2004,25 (8) :634-641.
3崔健昆,那坤.C反应蛋白与冠心病的相关性的研究[J].世界中西医结合杂志,2010,5(1):70-71. 被引量：2
4Fragasso G, Piatti PM, Monti L, et al. Short and long-term beneficial effects of partial free fatty acid inhibition in diabetic patients with schemic dilated cardiomyopathy [ J ]. Am Heart J,2003,46 ( 15 ) : E18.
5慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量：2414
6Sambandam N. Lopaschuk GD, Brownsey RW, et al. Energy metabo- lism in the hypertrophied heart [ J]. Heart Failure Rev, 2002,7 ( 2 ) : 161-173.
7Alonso-martinez JL, Lioreute-Diez B, Echegaray-Agara M, et al. C-re- active protein as a predictor of improvement and readmission in heart failure [ J ]. Eur J Heart Fail,2002,4 ( 3 ) :331-336.
8Lopaschuk GD, Barr R,Thomas PD,et al. Beneficial effects of trimeta- zidine in ex vivo working isehemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of longchain 3-ketoacyl coen- zyme a thiolase [ J ]. Circ Res ,2003 ,93 (3) : E33-37.
9王新兰,汪晓洲.曲美他嗪治疗缺血性心肌病的长期疗效及其对C反应蛋白的影响[J].临床荟萃,2009,24(6):531-532. 被引量：2

二级参考文献10

1Berton G, Cordiano R, Palmieri R, et al. C-reactive protein in acute myocardial infarction: association with heart failure[J]. Am Heart J,2003,145(6) :1094-1101.
2Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure[J]. Eur J Heart Fail, 2002,4 (3):331-336.
3Detry JM, Leclereg PJ. TEMS study trimetazidine vs propranolol in patients with stable angina peetoris:contribution of electric cardiogram monitoring [J]. Am J Cardiol, 1995, 76 (6) :8B-11B.
4Fragasso G, Piatti PM, Monti L, et al. Short and long-term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated eardiomyopathy[J]. Am Heart J, 2003,146(5) : E18.
5Lopasehuk GD,Barr R, Thomas PD, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long- chain 3-ketoacyl coenzyme a thiolase[J]. Circ Res, 2003,93(3): e33-37.
6Zwaka TP, Hombach V, Torzewski J. C - reactive protein mediated low density lipoprotein uptake by macrophages : implications for atherosclerosis[ J]. Circulation,2001,103(9) :1 194 - 1 197.
7Yeh ET, Anderson HV, Pasceri V, et al. C - reactive protein linking inflammation to cardiovascular complications[J]. Circulation, 2001, 104(9) :974 -975.
8Du clos TW. Function of C - reactive Protien[ J]. Ann Med ,2000,32 (4) :274 -278.
9Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
10张嘉莹,朱中玉,李牧蔚,陈岩,王现青.青年急性心肌梗死患者脂蛋白(a)水平的变化及其意义[J].临床心血管病杂志,2002,18(10):500-502. 被引量：248